#jn1 — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #jn1, aggregated by home.social.
-
Vacinas contra covid-19 serão atualizadas contra novas variantes
-
Vacinas contra covid-19 serão atualizadas contra novas variantes
-
conscientious objector🇨🇭🪂 @[email protected] (🇲) Es gibt fast überall #Biontech #NP8. Es gibt aber auch #Novavax #JN1. Zumindest in der #Reisepraxis :syslink: BCRT -
conscientious objector🇨🇭🪂 @[email protected] (🇲) Es gibt fast überall #Biontech #NP8. Es gibt aber auch #Novavax #JN1. Zumindest in der #Reisepraxis :syslink: BCRT -
Die Impfung für NP8.1 von Biontech gibt es ja vielerorts. Aber es ist auch eine Impfung gegen JN1 erhältlich mit dem Impfstoff von Novavax in der Reisepraxis BCRT an vielen Orten in Deutschland. In Berlin in der Friedrichstraße sind vermutlich zeitnah keine Termine frei, aber in Steglitz (Globetrotter, obere Etage) ist es ohne Termin möglich.
#Covid #COVID19 #corona #sars #Impfung #biontech #novavax #np8 #np81 #jn1
-
Die Impfung für NP8.1 von Biontech gibt es ja vielerorts. Aber es ist auch eine Impfung gegen JN1 erhältlich mit dem Impfstoff von Novavax in der Reisepraxis BCRT an vielen Orten in Deutschland. In Berlin in der Friedrichstraße sind vermutlich zeitnah keine Termine frei, aber in Steglitz (Globetrotter, obere Etage) ist es ohne Termin möglich.
#Covid #COVID19 #corona #sars #Impfung #biontech #novavax #np8 #np81 #jn1
-
Impfmöglichkeit Booster Auffrischung 💉Grippe #Sanofi #Novavax #Nuvaxovid #JN.1 #Biontech #Comirnaty #L.P.8.1 📆Termine ab 27.11. 🏥Elefanten Apotheke 📍Dörpfeldstr. 46 12489 #Berlin #Adlershof 📞03067894942 📧 [email protected] #COVID19 #CovidIsNotOver #TeamVorsicht #Impfung #nuvax25 #impflp81
-
⬆️ Impfmöglichkeit Booster Auffrischung 💉 #Novavax #Nuvaxovid #JN.1 📍 #Aachen #NRW 📆 mit Termin (📞); Termine ab 29.11.25 📞 0241-91993694 🚦Ü12. Stikotreue unklar, gern berichten. @drmccoy.info @safeairdocs.bsky.social @bildungabersicher.net #COVID19 #CovidIsNotOver #TeamVorsicht #Impfung #nuvax25
-
Falls ihr euch fragt, wie sicher die Impfung ist:
Dänische Forscher:innen haben sich die Boosterimpfung aus der Periode 2024/25 angeschaut. Bei mehr als einer Millione geimpfter Personen wurde kein statistisch auffälliger Wert von unerwünschten Ereignissen im Vergleich zur nicht-geimpften Bevölkerung gefunden.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2836889
-
Effectiveness of #BNT162b2 and #mRNA-1273 #JN1-adapted #vaccines against #COVID19-associated #hospitalisation and #death ..., https://etidiohnew.blogspot.com/2025/07/effectiveness-of-bnt162b2-and-mrna-1273.html
-
Effectiveness of #BNT162b2 and #mRNA-1273 #JN1-adapted #vaccines against #COVID19-associated #hospitalisation and #death ..., https://etidiohnew.blogspot.com/2025/07/effectiveness-of-bnt162b2-and-mrna-1273.html
-
#Malaysia, #Covid19: Health Ministry urges high-risk groups to get vaccinated amid #JN1 #subvariant spread https://www.malaymail.com/news/malaysia/2025/06/12/covid-19-health-ministry-urges-high-risk-groups-to-get-vaccinated-amid-jn1-subvariant-spread/180121
-
#Malaysia, #Covid19: Health Ministry urges high-risk groups to get vaccinated amid #JN1 #subvariant spread https://www.malaymail.com/news/malaysia/2025/06/12/covid-19-health-ministry-urges-high-risk-groups-to-get-vaccinated-amid-jn1-subvariant-spread/180121
-
Feverʼs pretty much gone. Inanahi was pretty miserable. Still, better than getting the plague. #COVID19 #JN1 #vaccination
-
Feverʼs pretty much gone. Inanahi was pretty miserable. Still, better than getting the plague. #COVID19 #JN1 #vaccination
-
Numb arm and fever, but better than getting the actual thing! #COVID19 #JN1 #vaccination
-
Numb arm and fever, but better than getting the actual thing! #COVID19 #JN1 #vaccination
-
-
-
#XBB.1.5 monovalent #vaccine induces lasting cross-reactive responses to #SARS-CoV-2 #variants such as HV.1 and #JN1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific #antibodies, https://etidiohnew.blogspot.com/2025/03/xbb15-monovalent-vaccine-induces.html
-
#XBB.1.5 monovalent #vaccine induces lasting cross-reactive responses to #SARS-CoV-2 #variants such as HV.1 and #JN1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific #antibodies, https://etidiohnew.blogspot.com/2025/03/xbb15-monovalent-vaccine-induces.html
-
Impfaktion am 18.1. 2025 in #berlinmitte
#Comirnaty #JN1 (Alter ab 6 Monate)
und
#Novavax #Nuvaxovid #JN1 (ab 12 Jahren).Kosten: 15€/Impfling.
Für Voranmeldung Mail-Adresse bei uns erfragen.
-
Impfaktion am 18.1. 2025 in #berlinmitte
#Comirnaty #JN1 (Alter ab 6 Monate)
und
#Novavax #Nuvaxovid #JN1 (ab 12 Jahren).Kosten: 15€/Impfling.
Für Voranmeldung Mail-Adresse bei uns erfragen.
-
Impfaktion am 18.1. 2025 in #berlinmitte
#Comirnaty #JN1 (Alter ab 6 Monate)
und
#Novavax #Nuvaxovid #JN1 (ab 12 Jahren).Kosten: 15€/Impfling.
Für Voranmeldung Mail-Adresse bei uns erfragen.
-
Impfaktion am 18.1. 2025 in #berlinmitte
#Comirnaty #JN1 (Alter ab 6 Monate)
und
#Novavax #Nuvaxovid #JN1 (ab 12 Jahren).Kosten: 15€/Impfling.
Für Voranmeldung Mail-Adresse bei uns erfragen.
-
Impfaktion am 18.1. 2025 in #berlinmitte
#Comirnaty #JN1 (Alter ab 6 Monate)
und
#Novavax #Nuvaxovid #JN1 (ab 12 Jahren).Kosten: 15€/Impfling.
Für Voranmeldung Mail-Adresse bei uns erfragen.
-
[Correspondence] #Antiviral humoral #immunity induced by #JN1 monovalent #mRNA #vaccines against SARS-CoV-2 omicron subvariants including #JN1, #KP311, and #XEC https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00810-7/fulltext?rss=yes
Our data suggest that the receptor-binding domain of JN.1 S can effectively induce antiviral humoral immunity against JN.1 subvariants and XEC comparable to the full-length JN.1 S.
-
[Correspondence] #Antiviral humoral #immunity induced by #JN1 monovalent #mRNA #vaccines against SARS-CoV-2 omicron subvariants including #JN1, #KP311, and #XEC https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00810-7/fulltext?rss=yes
Our data suggest that the receptor-binding domain of JN.1 S can effectively induce antiviral humoral immunity against JN.1 subvariants and XEC comparable to the full-length JN.1 S.
-
[Correspondence] #Antiviral humoral #immunity induced by #JN1 monovalent #mRNA #vaccines against SARS-CoV-2 omicron subvariants including #JN1, #KP311, and #XEC https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00810-7/fulltext?rss=yes
Our data suggest that the receptor-binding domain of JN.1 S can effectively induce antiviral humoral immunity against JN.1 subvariants and XEC comparable to the full-length JN.1 S.
-
[Correspondence] #Antiviral humoral #immunity induced by #JN1 monovalent #mRNA #vaccines against SARS-CoV-2 omicron subvariants including #JN1, #KP311, and #XEC https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00810-7/fulltext?rss=yes
Our data suggest that the receptor-binding domain of JN.1 S can effectively induce antiviral humoral immunity against JN.1 subvariants and XEC comparable to the full-length JN.1 S.
-
[Correspondence] #Antiviral humoral #immunity induced by #JN1 monovalent #mRNA #vaccines against SARS-CoV-2 omicron subvariants including #JN1, #KP311, and #XEC https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00810-7/fulltext?rss=yes
Our data suggest that the receptor-binding domain of JN.1 S can effectively induce antiviral humoral immunity against JN.1 subvariants and XEC comparable to the full-length JN.1 S.
-
Gibt es eigentlich Studien darüber,
a) welche Wirkung es genauer hat, wenn man 7, 8, 9 … Mal geimpft ist;
b) welche Wirkung eine Impfung auf den Verlauf hat, wenn man sich zufällig kurz darauf infiziert?
Beide Fragen scheinen eher unbeachtet.
#CovidIsNotOver #ImpfenSchützt #Kontrollgruppe #Corona #jn1 #kp2
-
Gibt es eigentlich Studien darüber,
a) welche Wirkung es genauer hat, wenn man 7, 8, 9 … Mal geimpft ist;
b) welche Wirkung eine Impfung auf den Verlauf hat, wenn man sich zufällig kurz darauf infiziert?
Beide Fragen scheinen eher unbeachtet.
#CovidIsNotOver #ImpfenSchützt #Kontrollgruppe #Corona #jn1 #kp2
-
Robust #antiviral humoral #immunity induced by #JN1 monovalent #mRNA #vaccines against a broad range of #SARS-CoV-2 #Omicron subvariants including #JN1, #KP311 and #XEC
Source: BioRxIV, AbstractAs of November 2024, SARS-CoV-2 Omicron JN.1 subvariants, such as KP.2 (JN.1.11.1.2), KP.3 (JN.1.11.1.3), KP.3.1.1 (JN.1.11.1.3.1.1), and XEC, a recombinant lineage between KS.1.1 (JN.13.1.1.1) and KP.3.3 (JN.1.11.1.3.3), have been circulating in several countries. To control…
-
Robust #antiviral humoral #immunity induced by #JN1 monovalent #mRNA #vaccines against a broad range of #SARS-CoV-2 #Omicron subvariants including #JN1, #KP311 and #XEC
Source: BioRxIV, AbstractAs of November 2024, SARS-CoV-2 Omicron JN.1 subvariants, such as KP.2 (JN.1.11.1.2), KP.3 (JN.1.11.1.3), KP.3.1.1 (JN.1.11.1.3.1.1), and XEC, a recombinant lineage between KS.1.1 (JN.13.1.1.1) and KP.3.3 (JN.1.11.1.3.3), have been circulating in several countries. To control…
-
Robust #antiviral humoral #immunity induced by #JN1 monovalent #mRNA #vaccines against a broad range of #SARS-CoV-2 #Omicron subvariants including #JN1, #KP311 and #XEC
Source: BioRxIV, AbstractAs of November 2024, SARS-CoV-2 Omicron JN.1 subvariants, such as KP.2 (JN.1.11.1.2), KP.3 (JN.1.11.1.3), KP.3.1.1 (JN.1.11.1.3.1.1), and XEC, a recombinant lineage between KS.1.1 (JN.13.1.1.1) and KP.3.3 (JN.1.11.1.3.3), have been circulating in several countries. To control…
-
Robust #antiviral humoral #immunity induced by #JN1 monovalent #mRNA #vaccines against a broad range of #SARS-CoV-2 #Omicron subvariants including #JN1, #KP311 and #XEC
Source: BioRxIV, AbstractAs of November 2024, SARS-CoV-2 Omicron JN.1 subvariants, such as KP.2 (JN.1.11.1.2), KP.3 (JN.1.11.1.3), KP.3.1.1 (JN.1.11.1.3.1.1), and XEC, a recombinant lineage between KS.1.1 (JN.13.1.1.1) and KP.3.3 (JN.1.11.1.3.3), have been circulating in several countries. To control…
-
Robust #antiviral humoral #immunity induced by #JN1 monovalent #mRNA #vaccines against a broad range of #SARS-CoV-2 #Omicron subvariants including #JN1, #KP311 and #XEC
Source: BioRxIV, AbstractAs of November 2024, SARS-CoV-2 Omicron JN.1 subvariants, such as KP.2 (JN.1.11.1.2), KP.3 (JN.1.11.1.3), KP.3.1.1 (JN.1.11.1.3.1.1), and XEC, a recombinant lineage between KS.1.1 (JN.13.1.1.1) and KP.3.3 (JN.1.11.1.3.3), have been circulating in several countries. To control…
-
Neutralizing #Activity and Viral #Escape of #Pemivibart by #SARS-CoV-2 #JN1 #sublineages
Source: BioRxIV, AbstractPemivibart (Pemgarda/VYD222) was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) on March 22, 2024, for COVID-19 pre-exposure prophylaxis in immunocompromised individuals. However, its efficacy and resistance against JN.1 sublineages have yet to be fully characterized. Here, we first assessed the neutralizing…
-
Neutralizing #Activity and Viral #Escape of #Pemivibart by #SARS-CoV-2 #JN1 #sublineages
Source: BioRxIV, AbstractPemivibart (Pemgarda/VYD222) was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) on March 22, 2024, for COVID-19 pre-exposure prophylaxis in immunocompromised individuals. However, its efficacy and resistance against JN.1 sublineages have yet to be fully characterized. Here, we first assessed the neutralizing…
-
#SARS-CoV-2 #JN1 reveals attenuated #pathogenicity and #airborne #transmission
Source: BioRxIV, AbstractJN.1 is a subvariant of SARS-CoV-2 Omicron BA.2.86 lineage that was predominant worldwide in early 2024, of which the in vivo characteristics are largely unknown. Our results demonstrated that the replication of JN.1 was more efficient than that of the parental BA.2 in Vero cells, which demonstrated low dependence on TMPRSS2. Compared to Omicron variants BA.2 and XBB…
-
#SARS-CoV-2 #JN1 reveals attenuated #pathogenicity and #airborne #transmission
Source: BioRxIV, AbstractJN.1 is a subvariant of SARS-CoV-2 Omicron BA.2.86 lineage that was predominant worldwide in early 2024, of which the in vivo characteristics are largely unknown. Our results demonstrated that the replication of JN.1 was more efficient than that of the parental BA.2 in Vero cells, which demonstrated low dependence on TMPRSS2. Compared to Omicron variants BA.2 and XBB…
